FDA Inspection 1219707 — Boehringer Ingelheim Pharmaceuticals, Inc.
The FDA completed an inspection of Boehringer Ingelheim Pharmaceuticals, Inc. on Sep 22, 2023 in Ridgefield, CT. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Sep 22, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Ridgefield, CT (United States)
Additional Details
Sponsor, Contract Research Organization